ArticlePloS one2019
Detecting drug-drug interactions using artificial neural networks and classic graph similarity measures.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A comprehensive landscape of AI applications in broad-spectrum drug interaction prediction: a systematic review.Journal of cheminformatics · 2025Review
- Graph neural network-based drug-drug interaction prediction.Scientific reports · 2025Article
- Advancing ADMET prediction for major CYP450 isoforms: graph-based models, limitations, and future directions.Biomedical engineering online · 2025Review
- Artificial Intelligence Models and Tools for the Assessment of Drug-Herb Interactions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- DRGATAN: Directed relation graph attention aware network for asymmetric drug-drug interaction prediction.iScience · 2024Article
- Eravacycline, an antibacterial drug, repurposed for pancreatic cancer therapy: insights from a molecular-based deep learning model.Briefings in bioinformatics · 2024Article
- Deep learning for drug-drug interaction prediction: A comprehensive review.Quantitative biology (Beijing, China) · 2024Review
- Multimodal CNN-DDI: using multimodal CNN for drug to drug interaction associated events.Scientific reports · 2024Article
- PRID: Prediction Model Using RWR for Interactions between Drugs.Pharmaceutics · 2023Article
- The importance of graph databases and graph learning for clinical applications.Database : the journal of biological databases and curation · 2023Review
- Article
- Predicting drug characteristics using biomedical text embedding.BMC bioinformatics · 2022Article
- CDCDB: A large and continuously updated drug combination database.Scientific data · 2022Article
- On the road to explainable AI in drug-drug interactions prediction: A systematic review.Computational and structural biotechnology journal · 2022Review
- Article
- On the robustness of generalization of drug-drug interaction models.BMC bioinformatics · 2021Article
- A machine learning framework for predicting drug-drug interactions.Scientific reports · 2021Article
- Multimorbidity prediction using link prediction.Scientific reports · 2021Article
- A neural network-based method for polypharmacy side effects prediction.BMC bioinformatics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-drug interactions are preventable causes of medical injuries and often result in doctor and emergency room visits. Computational techniques can be used to predict potential drug-drug interactions. We approach the drug-drug interaction prediction problem as a link prediction problem and present two novel methods for drug-drug interaction prediction based on artificial neural networks and factor propagation over graph nodes: adjacency matrix factorization (AMF) and adjacency matrix factorization with propagation (AMFP). We conduct a retrospective analysis by training our models on a previous release of the DrugBank database with 1,141 drugs and 45,296 drug-drug interactions and evaluate the results on a later version of DrugBank with 1,440 drugs and 248,146 drug-drug interactions. Additionally, we perform a holdout analysis using DrugBank. We report an area under the receiver operating characteristic curve score of 0.807 and 0.990 for the retrospective and holdout analyses respectively. Finally, we create an ensemble-based classifier using AMF, AMFP, and existing link prediction methods and obtain an area under the receiver operating characteristic curve of 0.814 and 0.991 for the retrospective and the holdout analyses. We demonstrate that AMF and AMFP provide state of the art results compared to existing methods and that the ensemble-based classifier improves the performance by combining various predictors. Additionally, we compare our methods with multi-source data-based predictors using cross-validation. In the multi-source data comparison, our methods outperform various ensembles created using 29 different predictors based on several data sources. These results suggest that AMF, AMFP, and the proposed ensemble-based classifier can provide important information during drug development and regarding drug prescription given only partial or noisy data. Additionally, the results indicate that the interaction network (known DDIs) is the most useful data source for identifying potential DDIs and that our methods take advantage of it better than the other methods investigated. The methods we present can also be used to solve other link prediction problems. Drug embeddings (compressed representations) created when training our models using the interaction network have been made public.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.